From Innovation To Impact: Building On Pittsburgh's Legacy To Industrialize Advanced Therapies

By Katie Shannon, VP, Site Head, BaseCamp Pittsburgh

The piece argues that the future of genetic medicine hinges on moving from bespoke laboratory science to industrial‑scale, reliable manufacturing—an evolution mirrored by Pittsburgh’s broader transformation from steel to life sciences. It describes a new biomanufacturing center at Hazelwood Green designed to standardize and automate complex cell and gene therapy production, with flexible suites supporting multiple modalities and a digitally integrated environment for end‑to‑end cGMP workflows. The site aligns with national priorities to expand domestic biomanufacturing capacity and workforce readiness, and is projected to be operational in 2027, offering significant regional job creation while helping reduce costs and increase scalability for advanced therapies.

Context includes a longstanding partnership with the University of Pittsburgh to establish the Pitt BioForge BioManufacturing Center, backed by a $100M grant—part of a multi‑year effort to build a strategic life‑sciences hub in the city and catalyze industrialization of cell and gene therapies.